Related Experiment Video
Updated: Mar 14, 2026
05:53
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
10.8K
Patient experiences with pharmacogenetic testing in a primary care setting
Susanne B Haga1, Rachel Mills1, Jivan Moaddeb1
1Center for Applied Genomics & Precision Medicine, Duke University School of Medicine, 304 Research Drive, Durham, NC 27708, USA.
Pharmacogenomics
|September 21, 2016
Summary
Patients found pharmacogenetic (PGx) testing useful for guiding treatment decisions. However, enhancing patient-provider communication about PGx test results is crucial for better understanding and application.
Area of Science:
- Pharmacogenomics
- Clinical Pharmacy
- Patient Experience Research
Background:
- Pharmacogenetic (PGx) testing offers potential for personalized medicine by predicting drug response.
- Understanding patient perspectives is vital for successful integration of PGx testing into clinical practice.
Purpose of the Study:
- To investigate patient experiences and perceptions of pharmacogenetic (PGx) testing.
- To assess patient interest in and understanding of PGx testing results.
Main Methods:
- Patients undergoing pharmacist-assisted PGx testing were surveyed pre- and post-testing.
- Data collection included patient interest, provider communication, and result comprehension.
Main Results:
- The primary driver for PGx testing interest was to inform optimal treatment selection.
- A majority of patients who completed follow-up surveys reported discussing results with their provider.
- While patients found PGx testing useful, comprehension of results varied, with some understanding them well.
Conclusions:
- Patients generally perceive pharmacogenetic testing as valuable for guiding therapeutic choices.
- Improvements in patient-provider communication are necessary to enhance the understanding and utility of PGx test results.
Related Concept Videos
01:29Pharmacogenetics and Pharmacogenomics: Overview
117
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
117
01:27Pharmacogenetics of Drug Metabolism: Overview
88
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
88
01:27Principles of Pharmacogenetics: Types of Genetic Variants
72
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
72
01:29Pharmacogenomics: Identification of New Drug Targets
73
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
73
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
93
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
93
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
90
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
90